Company intelligence / Profile preview

HEMA Biologics

Louisville, Kentucky, United Stateshemabio.com ↗

Ownership: Private
Employees: ~27
Development stage: Other

Overview

HEMA Biologics has achieved FDA approval for SEVENFACT® [coagulation factor VIIa (recombinant)-jncw], a treatment for hemophilia A or B with inhibitors. The company is focused on rare bleeding disorders and aims to bring innovative therapies to the U.S. market, leveraging both plasma-based and recombinant technologies from its manufacturing partner LFB.[3][4][5] No additional clinical results are detailed in the available sources.

Therapeutic areas: Hematology
Modalities: Recombinant proteins (notably recombinant coagulation factors)[5]Plasma-derived products[4]
Industry: Biotech

Drug pipeline

2 assets

factor vii

Unknown

1 more asset in the full pipeline.

Partnerships

LFB (global leader in plasma-based products and recombinant technology, manufacturer of HEMA’s products)[4]

Beyond the preview

Go deeper on HEMA Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEMA Biologics.